ClinicalTrials.gg
Not yet recruitingNCT07475962STEA-DT1Updated Mar 23, 2026

Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes

An observational study in Type 1 Diabetes, Liver Steatoses and MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by Institut de Recherches Cliniques de Montreal. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Institut de Recherches Cliniques de Montreal · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Institut de Recherches Cliniques de Montreal.

Started
2026
with 4 others
Observational
4 of 42
2 open now
Registered
39th of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal, this one is one of 5 that started in 2026, is one of 4 observational ones, and was the 39th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal, or all of them as a file.
02

Study summary

The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older living with type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) in Quebec.

The main questions it aims to answer are:

  1. What is the prevalence and severity of liver steatosis and fibrosis among people living with type 1 diabetes in Québec?
  2. Are there patients with type 1 diabetes who have advanced, undiagnosed stages of liver disease that require management but are missed by current standard care practices?

Researchers will compare three participant subgroups based on adiposity (a control group without increased adiposity, an overweight group with increased adiposity, and an obesity group with increased adiposity) to see if the prevalence and severity of hepatic steatosis and fibrosis are highest in the obesity group and lowest in the control group. They will also explore if variables and potential risk factors associated with liver disease differ across these subgroups.

Participants will attend a single study visit where they will be asked to:

  • Provide clinical data through laboratory analyses.
  • Undergo specific clinical procedures.
  • Complete validated questionnaires.
03

Conditions studied

  • Type 1 Diabetes
  • Liver Steatoses
  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Liver Fibrosis
  • Latent Autoimmune Diabetes in Adult (LADA)

Keywords

  • MASLD
  • Liver steatosis
  • Liver fibrosis
  • LADA
  • Body composition
  • Type 1 diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of 100 adults (aged 18 years and older) living with type 1 diabetes or LADA for at least one year.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals ≥ 18 years of age.
  • A clinical diagnosis of type 1 diabetes or Latent Diabetes in Adults (LADA) for at least one year, as per the investigators' clinical judgment (confirmatory C-peptide and antibodies will not be required).

Exclusion criteria

Exclusion Criteria:

  • Alcohol consumption exceeding 20g per day in women or 30g per day in men.
  • Known chronic liver disease (including viral, drug-induced, Wilson disease, deficit in alpha-1-antirypsin, hemochromatosis, hepatitis, etc.).
  • Evidence of cirrhosis based on a result of liver , or history of portal hypertension presented by ascites, hepatic encephalopathy or varices.
  • History of use of medications known to induce liver steatosis, including , high-dose estrogens, tamoxifen, methotrexate, amiodarone, or tetracycline.
  • Ongoing pregnancy.
  • of less than 5 years, as per investigators' clinical judgment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Target follow-up
3 Days
Patient registry
Yes

Groups and cohorts

  • Control group

    Adults with type 1 diabetes or LADA without increased adiposity and without any BMI-based criterion.

    Other: Adiposity and BMI Classification

  • Overweight group

    Adults with T1D or LADA with a BMI between 25.0 and 29.9 kg/m² combined with increased adiposity

    Other: Adiposity and BMI Classification

  • Obesity Group

    Adults with T1D or LADA with a BMI of 30 kg/m² or higher combined with increased adiposity.

    Other: Adiposity and BMI Classification

Interventions

  • OtherAdiposity and BMI Classification

    Participants are classified into three subgroups based on their BMI and the presence of increased adiposity. Increased adiposity is defined by waist circumference, waist-to-hip ratio, or waist-to-height ratio exceeding sex- and ethnicity-specific thresholds. The subgroups are: a control group (no increased adiposity), an overweight group (BMI 25.0-29.9 kg/m² with increased adiposity), and an obesity group (BMI ≥ 30 kg/m² with increased adiposity).

06

What researchers measure

Primary outcomes

  1. Assessment of liver fibrosis using FibroScan

    Liver fibrosis severity will be quantified using liver stiffness measurement (LSM) obtained via FibroScan. The measurement is expressed in kilopascals (kPa). Higher values indicate more severe fibrosis, categorized as: \< 8.0 kPa (Normal), 8.0 to 9.6 kPa (Significant fibrosis), 9.7 to 13.5 kPa (Advanced fibrosis), and \> 13.5 kPa (Cirrhosis)

    Time frame: Baseline (Day 1 / Single Study Visit)

  2. Degree of liver steatosis assessment

    Liver steatosis will be quantified using the Controlled Attenuation Parameter CAP value generated simultaneously during the FibroScan assessment. The measurement is expressed in decibels per meter (dB/m). Higher values indicate a higher degree of steatosis, categorized as: \< 294 dB/m (\<5% steatosis), 294 to 310 dB/m (5 to 30%), 311 to 330 dB/m (30 to 60%), and \> 330 dB/m (\>60%).

    Time frame: Baseline (Day 1 / Single Study Visit)

Secondary outcomes

  1. Anthropometric Assessment: Body mass Index (BMI)

    Body mass index (BMI: kg/m\^2) will be calculated using weight (kg) and height (cm) to compare FibroScan results across predefined subgroups.

    Time frame: Baseline (Day 1 / Single Study Visit)

  2. Anthropometric Assessment: Waist circumference

    Waist circumference and hip circumference (cm) will be used to compare FibroScan results across predefined subgroups.

    Time frame: Baseline (Day 1 / Single Study Visit)

  3. Adiposity-Based Subgroup Classification

    Participants will be categorized into three groups (e.g., Low, Medium, High adiposity) based on a composite of iDXA

    Time frame: Baseline (Day 1 / Single Study Visit)

Other outcomes

  1. Alcohol Use Disorders Identification Test (AUDIT) Score

    Total score from the 10-item AUDIT questionnaire to assess alcohol consumption. Range: 0 to 40. A higher score indicates a greater risk of hazardous and harmful alcohol use, as well as potential alcohol dependence (A score of 8 or more is typically considered the threshold for hazardous drinking).

    Time frame: Baseline (Day 1 / Single Study Visit)

  2. Physical Activity Level (IPAQ)

    Total physical activity expressed as Metabolic Equivalent of Task (MET)-minutes per week. A higher score (higher MET-minutes/week) indicates a higher level of physical activity.

    Time frame: Baseline (Day 1 / Single Study Visit)

  3. Eating Behavior (Three-Factor Eating Questionnaire: TFEQ)

    The TFEQ-R18 is an 18-item validated tool used to assess three domains of eating behavior: Cognitive Restraint, Uncontrolled Eating, and Emotional Eating. Raw scores are transformed to a 0-100 scale. For all sub-scales, higher scores indicate a greater presence of that specific eating behavior (e.g., higher emotional eating or higher restraint).

    Time frame: Baseline (Day 1 / Single Study Visit)

  4. Dietary Intake (RxFood Diary)

    Average daily caloric intake calculated over 3 days

    Time frame: Baseline (Day 1 / Single Study Visit)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Souza M, Al-Sharif L, Khalil SM, Villela-Nogueira CA, Mantovani A. Global Epidemiology and Characteristics of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 1 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2025 Jul;23(8):1308-1319.e17. doi: 10.1016/j.cgh.2024.09.038. Epub 2024 Dec 11. PubMed 39672250 ↗
  • European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7. PubMed 38851997 ↗
  • Lalanne-Mistrih ML, Bonhoure A, Messier V, Boudreau V, Lebbar M, Talbo MK, Sun CJ, Bandini A, Secours L, Calderon V, Grou C, Tressieres B, Brazeau AS, Rabasa-Lhoret R. Overweight and Obesity in People Living With Type 1 Diabetes: A Cross-Sectional Analysis of the BETTER Registry. Diabetes Metab Res Rev. 2024 Sep;40(6):e3837. doi: 10.1002/dmrr.3837. PubMed 39193662 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 17, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
May 30, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07475962
Lead sponsor
Institut de Recherches Cliniques de Montreal
Responsible party
Sarah Beland Bonenfant (Clinical Professor, Institut de Recherches Cliniques de Montreal) — Principal investigator
First posted
Mar 17, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Élisabeth Nguyen, DtP, M.Sc
Contact
elisabeth.nguyen@ircm.qc.ca
(514) 987-5617
Valérie Parent
Contact
valerie.parent@ircm.qc.ca
Sarah Béland-Bonenfant, M.D. Ph.D
principal investigator · Institut de Recherches Cliniques de Montreal
Rémi Rabasa-Lhoret, M.D. Ph.D
principal investigator · Institut de Recherches Cliniques de Montreal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion